Neisseria meningitidis lipopolysaccharides in human pathology

Journal of Endotoxin Research

Volumn 7, Issue 6, 2001, Pages 401-420

  Brandtzaeg, P ^a   Bjerre, A ^a   Ovsteo R ^a   Brusletto, B ^a   Joo G B ^a   Kierulf, P ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; ENDOTOXIN; LIPID A; OLIGOSACCHARIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; THROMBOPLASTIN;

ANTIBIOTIC THERAPY; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD LEVEL; CARBOHYDRATE ANALYSIS; CEREBROSPINAL FLUID LEVEL; CIRCULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FIBRINOLYSIS; HALF LIFE TIME; HUMAN; HUMAN CELL; INFLAMMATION; LIMULUS LYSATE TEST; MENINGITIS; MENINGOCOCCEMIA; MORTALITY; MULTIPLE ORGAN FAILURE; NEISSERIA MENINGITIDIS; NONHUMAN; PATHOLOGY; REVIEW; SEPTIC SHOCK; SEPTICEMIA; SKIN DEFECT; SUBARACHNOID SPACE; SYMPTOM; THROMBOSIS;

BACTERIA (MICROORGANISMS); LIMULUS; NEISSERIA; NEISSERIA MENINGITIDIS;

EID: 0035680132     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805101101533016     Document Type: Review

References (185)

1. Mémoire sur la maladie qui a régné a Genève au printemps de 1805
2. Ueber die Aetiologie der akuten Meningitis cerebrospinalis
3. A case of acute meningococcal septicaemia
4. A case of suprarenal apoplexy
5. Nebennierenapoplexie bei kleinen
6. Versuche zur Gewinnung und Wertbestimmung eines Meningococcenserums
7. Versuche zur Serodiagnostik und Serotherapie der epidemischen Genickstarre
8. La Méningite Cérebro-spinale
9. Serum treatment of epidemic cerebro-spinal meningitis
10. The results of the serum treatment in thirteen hundred cases of epidemic meningitis
11. Population genetics and molecular epidemiology of Neisseria meningitidis
12. Update on meningococcal disease with emphasis on pathogenesis and clinical management
13. Meningococcal carriage and disease
14. Uncloaking the meningococcus: Dynamics of carriage and disease
15. Pathogenetic events during infection of the human nasopharynx with Neisseria meningitidis and Haemophilus influenzae
16. Invasion of primary nasopharyngeal epithelial cells by Neisseria meningitidis is controlled by phase variation of multiple surface antigens
17. Pathogenesis of meningococcal infections
18. Plasma endotoxin as predictor of multiple organ failure and death in systemic meningococcal disease
19. Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock
20. Bacteremia and compartmentalization of LPS in meningococcal disease
21. Systemic meningococcal disease: Clinical pictures and pathophysiological background
22. Pathophysiology, treatment and outcome of meningococcemia: A review and recent experience
23. Pathophysiology of meningococcal sepsis in children
24. Epidemiology and pathogenesis of Neisseria meningitidis
25. Meningococcal disease
26. Gram-negative bacteria induce pro-inflammatory cytokine production by monocytes in the absence of lipopolysaccharide (LPS)
27. Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through Toll-like receptor 2
28. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via Toll-like receptor (TLR) 2 but not via TLR4/MD2
29. Dendritic cell activation and cytokine production induced by group B Neisseria meningitidis: Interleukin-12 production depends on lipopolysaccharide expression in intact bacteria
30. Contributions of Neisseria meningitidis LPS and non-LPS to pro-inflammatory cytokine response
31. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis
32. Pili and outer membrane appendages on Neisseria meningitidis in cerebrospinal fluid of an infant
33. Meningococcal endotoxin in lethal septic shock plasma studied by gas chromatography, mass-spectrometry, ultracentrifugation, and electron microscopy
34. Production, characterization and control of MenB-vaccine 'Folkehelsa': An outer membrane vesicle vaccine against group B meningococcal disease
35. Cellular activating properties and morphology of membrane-bound and purified meningococcal lipopolysaccharide
36. Immunoglobulin A1 protease, an exoenzyme of pathogenic Neisseriae, is a potent inducer of pro-inflammatory cytokines
37. Is lipid A the principal monocyte activating factor in meningococcal septic shock plasma?
38. Meningitidis bacterium is viable without endotoxin
39. Measurement of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage
40. Outer membrane vesicles from Neisseria meningitidis: Effects on cytokine production in human whole blood
41. Gene expression and production of tumor necrosis factor alpha, interleukin-1β (IL-1β), IL-8, macrophage inflammatory protein 1α (MIP-1α), MIP-1β, and gamma interferon-inducible protein 10 by human group B meningococcal outer membrane vesicles
42. Limulus antilipopolysaccharide factor protects rabbits from meningococcal endotoxin shock
43. Effect of polymyxin B on experimental shock from meningococcal and Escherichia coli endotoxins
44. Polymyxin-B inhibition of LPS-induced interleukin-1 secretion by human monocytes is dependent upon the LPS origin
45. Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes
46. Ability of gonococcal and meningococcal lipopolysaccharides to clot Limulus amebocyte lysate
47. Cardiovascular aspects of experimental sepsis in young and older awake piglets: Age-related differences
48. Structural characterization of the lipid A component of pathogenic Neisseria meningitidis
49. 5S No. 125
50. Genetic basis for biosynthesis, structure, and function of meningococcal lipopolysaccharide (endotoxin)
51. Lipopolysaccharide serotyping of Neisseria meningitidis by hemagglutination inhibition
52. Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes
53. The chemistry and biology of lipooligosaccharides: The endotoxins of bacteria of the respiratory and genital mucosae
54. Chemical synthesis of core structures
55. Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis
56. Meningococcal lipopolysaccharides: Virulence factor and potential vaccine component
57. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation
58. Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates
59. Phase variation of LPS directs interconversion of invasive and immuno-resistant phenotypes of Neisseria gonorrhoeae
60. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup B
61. Mannose-binding lectin: Structure, function, genetics and disease associations
62. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease
63. Bacterial endotoxin: Molecular relationships of structure to activity and function
64. Chemical structure of lipid A: Recent advances in structural analysis of biologically active molecules
65. Enzymatically deacylated Neisseria LPS inhibits murine splenocyte mitogenesis induced by LPS
66. Enzymatic deacylation of the lipid A moiety of Salmonella typhimurium lipopolysaccharides by human neutrophils
67. Internalization of lipopolysaccharide by phagocytes
68. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: Influence on lipopolysaccharide structure, toxicity and adjuvant activity
69. Lipid A engineering in vaccine development against Neisseria meningitidis
70. Lipooligosaccharides (LOS) of mucosal pathogens: Molecular mimicry and host-modification of LOS
71. Antigenic mimicry in Neisseria species
72. The structure of an R-type oligosaccharide core obtained from some lipopolysaccharides of Neisseria meningitidis
73. Structure of the L1 and L6 core oligosaccharide epitopes of Neisseria meningitidis
74. Structure of the L5 lipopolysaccharide core oligosaccharides of Neisseria meningitidis
75. Structure of the L2 lipopolysaccharide core oligosaccharides of Neisseria meningitidis
76. Structure of the sialylated L3 lipopolysaccharide of Neisseria meningitidis
77. Isolation and characterization of lipopolysaccharides, lipooligosaccharides, and lipid A
78. Meningococcal group A lipooligosaccharides (LOS): Preliminary structural studies and characterization of serotype-associated and conserved LOS epitopes
79. Structural basis of the Neisseria meningitidis immunotypes including L4 and L7 immunotypes
80. Heterogeneity and variation among Neisseria meningitidis lipopolysaccharides
81. Heterogeneity of molecular size and antigenic expression within the lipooligosaccharides of individual strains of Neisseria gonorrhoeae and Neisseria meningitidis
82. Heterogeneity of lipopolysaccharides of Neisseria meningitidis revealed by thin-layer chromatography combined with monoclonal antibodies
83. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies
84. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis
85. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity
86. Lipopolysaccharide phase variation in Haemophilus and Neisseria
87. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491
88. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58
89. Construction of acetate auxotrophs of Neisseria meningitidis to study host-meningococcal endotoxin interactions
90. Quantitation of endotoxin in blood from patients with meningococcal disease using a Limulus lysate test in combination with chromogenic substrate
91. Meningococcal septicaemia treated with combined plasmaphoresis and leucaphoresis or with blood exchange
92. Compartmentalization of lipopolysaccharide-production correlates with the clinical presentation in meningococcal disease
93. Correlation between pro-inflammatory cytokines and anti-inflammatory mediators and the severity of disease in meningococcal infections
94. Quantitative detection of bacterial lipopolysaccharides in clinical specimens
95. Pathophysiological responses to endotoxin in humans
96. Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock
97. No increase in endotoxin during antibiotic killing of meningococci
98. Induction of human endothelial tissue factor expression by Neisseria meningitidis: The influence of bacterial killing and adherence to the endothelium
99. Detection of circulating tumor necrosis factor after endotoxin administration
100. The complex pattern of cytokines in serum from patients with meningococcal septic shock
101. Local production of tumor necrosis factor α, interleukin 1, and interleukin 6 in meningococcal meningitis
102. Severe human septic shock involves more than tumor necrosis factor
103. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura
104. Age-related differences in outcome and severity of DIC in children with septic shock and purpura
105. Interleukin-10 and soluble tumor necrosis factor receptors in cerebrospinal fluid of children with bacterial meningitis
106. Production of interleukin-1-receptor antagonist during experimental endotoxaemia
107. The pattern of interleukin-1β (IL-1β) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections
108. Interleukin 1 potentiates the lethal effect of tumor necrosis factor α/cachectin in mice
109. Anti-inflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10 and IL-13
110. Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes
111. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: Identification of interleukin-10 as a major functional deactivator of human monocytes
112. Endotoxemia elicits increased circulating β2-INF/IL-6 in man
113. Interleukin-6 and its soluble receptor during acute meningococcal infections: Effect of plasma or whole blood exchange
114. Detection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of anti-inflammatory agents
115. IL-8 in septic shock, endotoxemia, and after IL-1 administration
116. Interleukin-8 in serum and cerebrospinal fluid from patients with meningococcal disease
117. The protective role of interleukin-10 in endotoxin shock
118. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock
119. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease
120. The relationship between plasminogen activator inhibitor-1 and pro-inflammatory and counterinflammatory mediators in children with meningococcal septic shock
121. Posttranscriptional down-regulation of tumor necrosis factor-alpha and interleukin-beta production in acute meningococcal infections
122. IL-12: A key cytokine in immune regulation
123. Interleukin-12 levels during the initial phase of septic shock with purpura in children: Relation to severity of disease
124. Intrathecal production of interleukin-12 and interferon-γ in patients with bacterial meningitis
125. Interferon in human serum after injection of endotoxin
126. Cytokine appearance in human endotoxemia and primate bacteremia
127. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: A prospective double-blind study
128. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-β and interleukin 10
129. Experimental endotoxemia in humans: Analysis of the cytokine release and coagulation, fibrinolytic and complement pathways
130. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin
131. Endotoxin and meningococcemia intravascular inflammation induced by native endotoxin in man
132. Complement levels in primates treated with anti-C5a antibodies
133. Complement activation and endotoxin levels in systemic meningococcal disease
134. The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation
135. Complement activation in relation to capillary leakage in children with septic shock and purpura
136. Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal complement complex and the vitronectin-thrombin-antithrombin complex
137. Increased excretion of urinary glycosaminoglycans in meningococcal septicemia and their relationship to proteinuria
138. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody
139. Pathogenesis of disseminated intravascular coagulation in sepsis
140. Cytokines: Triggers of clinical thrombotic disease
141. Bacterial lipopolysaccharide activates nuclear factor-κB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes
142. Bacterial lipopolysaccharide activates NF-κB through Toll-like receptor (TLR-4) in cultured human dermal endothelial cells
143. The occurrence and features of hemorrhagic skin lesions in 115 cases of systemic meningococcal disease
144. The cutaneous lesions in acute meningococcemia
145. Dysfunction of endothelial protein C activation in severe meningococcal sepsis
146. Rapid diagnosis of acute meningococcal infections by needle aspiration or biopsy of skin lesions
147. The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic coagulation pathway inhibitor and fibrinopeptide A in systemic meningococcal disease
148. Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases
149. Meningococcal septic shock in children: Clinical and laboratory features, outcome, and development of a prognostic score
150. Epidemic meningococcaemia and purpura fulminans with induced protein C deficiency
151. Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict a high mortality
152. Efficacy and safety of recombinant human activated protein C for severe sepsis
153. Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease
154. Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease
155. 4G/5G promotor polymorphism in the plasminogen activator inhibitor-1 gene and outcome of meningococcal disease
156. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia: In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons
157. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and pro-inflammatory attributes
158. The role of nitric oxide in sepsis - An overview
159. Factors in the prognosis of meningococcal infection
160. Severity of meningococcal disease: Assessment by factors and scores and implications for patient management
161. Meningococcal disease: A comparison of eight severity scores in 125 children
162. Intravenous endotoxin recruits a distinct subset of human neutrophils, defined by monoclonal antibody 31D8, from bone marrow to the peripheral circulation
163. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration
164. Investigation by scintigraphic methods of neutrophil kinetics under normal and septic shock conditions in the experimental baboon model
165. Functional and clinical aspects of the myelomonocyte protein calprotectin
166. 21)
167. Differential alternations in plasma colony-stimulating factor concentrations in meningococcemia
168. Bioactive cytidine deaminase, an inhibitor of granulocyte-macrophage-colony forming cells, is massively released in fulminant meningococcal sepsis
169. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to unfavourable prognosis
170. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis
171. A normal platelet count at admission in acute meningococcal disease does not exclude a fulminant course
172. Fulminant meningococcal septicemia: Dissociation between plasma thrombopoietin and platelet counts
173. Elevated VIP and plasma endotoxin in human Gram-negative septic shock
174. Vasoactive intestinal peptide in sepsis and shock
175. Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children
176. The role of Fc gamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement deficient individuals
177. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock
178. Variation in the tumor necrosis factor-α gene promotor region may be associated with death from meningococcal disease
179. Genetic influence on cytokine production and fatal meningococcal disease
180. Genetic influence on cytokine production in meningococcal disease
181. Randomized placebo-controlled trial of HA-1A, a human monoclonal anti-endotoxin antibody, in children with meningococcal septic shock
182. 21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
183. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5
184. Assessment of the effect of candidate anti-inflammatory treatment on the interaction between meningococci and inflammatory cells in vitro in a whole blood model
185. Parents' and GPs' key role in diagnosis of meningococcal septicaemia